Compare KINS & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | KINS | VCRE |
|---|---|---|
| Founded | 1886 | 2000 |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 279.5M | 271.7M |
| IPO Year | 2013 | 2026 |
| Metric | KINS | VCRE |
|---|---|---|
| Price | $22.93 | $11.04 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $24.48 |
| AVG Volume (30 Days) | ★ 93.7K | 17.4K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.03% | N/A |
| EPS Growth | ★ 94.59 | N/A |
| EPS | ★ 1.86 | N/A |
| Revenue | ★ $214,867,301.00 | N/A |
| Revenue This Year | $18.83 | $38.94 |
| Revenue Next Year | $15.85 | $694.23 |
| P/E Ratio | $12.49 | ★ N/A |
| Revenue Growth | ★ 38.50 | N/A |
| 52 Week Low | $13.83 | $7.88 |
| 52 Week High | $23.42 | $14.01 |
| Indicator | KINS | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 67.82 | 53.11 |
| Support Level | $18.35 | $8.83 |
| Resistance Level | N/A | $11.88 |
| Average True Range (ATR) | 0.86 | 0.44 |
| MACD | 0.33 | 0.16 |
| Stochastic Oscillator | 86.05 | 58.65 |
Kingstone Companies Inc offers property and casualty insurance products through its subsidiary engaged in writing business through retail and wholesale agents and brokers. Its products include Personal lines, Livery physical damage, and Others. It operates in single segment, property and casualty insurance. It derives substantially all of its revenue from KICO, including revenues from earned premiums, ceding commissions from quota share reinsurance, net investment income generated from its investment portfolio, and net realized gains and losses on investment securities.
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.